Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naproxen,Fexofenadine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : 5 Horizons Capital
Deal Size : Undisclosed
Deal Type : Financing
Sen-Jam Secures Investment for SJP-001 Clinical Trial with Novotech
Details : The financing aims to advance the clinical development of SJP-001. It is designed to help not only treat the signs and symptoms of Veisalgia (alcohol hangover).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : Naproxen,Fexofenadine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : 5 Horizons Capital
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Naproxen,Fexofenadine Hydrochloride
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sen-Jam Pharmaceutical Announces Ethics Approval for SJP-001 Trial
Details : SJP-001 is a combination of two OTC oral generic drugs (i.e., a NSAID (naproxen) and an H1-antagonist (fexofenadine), being investigated for inflammatory and metabolic health disorders.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Naproxen,Fexofenadine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Epaminurad,Naproxen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Epaminurad,Naproxen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2024
Lead Product(s) : Naproxen,Inapplicable
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Launches FDA-Approved Naproxen Delayed-Release Tablets
Details : Naproxen is an approved COX-1/COX-2 inhibitor. A generic of EC-Naprosyn, it is available as an enteric coated delayed release tablet for patients with RA, osteoarthritis and ankylosing spondylitis.
Product Name : EC-Naprosyn-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Naproxen,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen,Fexofenadine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alcohol Hangover Treatments and the Classification for Treating Hangovers as a Disease
Details : Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Naproxen,Fexofenadine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilaprazole,Naproxen,Aceclofenac,Celecoxib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Ilaprazole,Naproxen,Aceclofenac,Celecoxib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JP-1366,Aceclofenac,Meloxicam,Naproxen
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : JP-1366,Aceclofenac,Meloxicam,Naproxen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbidopa,Etilevodopa,Naproxen
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Northwestern Medical Group | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Novel Non-opioid Post-surgical Pain Treatment in Females
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : Carbidopa,Etilevodopa,Naproxen
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Northwestern Medical Group | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable